Literature DB >> 1318371

Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies.

M Facklam1, P Schoch, E P Bonetti, F Jenck, J R Martin, J L Moreau, W E Haefely.   

Abstract

Agonists at the benzodiazepine receptor (BZR) produce their effects through potentiation of the inhibitory alpha-aminobutyric acid-mediated neurotransmission in the central nervous system via positive allosteric modulation of the gamma-aminobutyric acidA receptor. Agonists with high intrinsic efficacy are anticonvulsant, anxiolytic, muscle relaxant and sedative, whereas agonists with low intrinsic efficacy (partial agonists) are predominantly anticonvulsant and anxiolytic, but antagonize muscle relaxant and sedative effects of full agonists. The four BZR ligands triazolam, diazepam, Ro 19-8022 (a benzoquinolizinone) and bretazenil (Ro 16-6028, an imidazobenzodiazepinone) were pharmacologically characterized in various neurological and behavioral paradigms in mice: two anticonvulsant tests (prevention of audiogenic and pentylenetetrazol-induced seizures), a conflict test which reveals both anxiolytic and sedative properties and two tests which mainly measure motor impairment (rotarod and horizontal wire test). Although triazolam and diazepam elicited an effect in all tests, Ro 19-8022 and bretazenil exhibited anticonvulsant and anxiolytic properties, but virtually failed to induce motor impairment and severe sedation. In separate experiments, fractional BZR occupancy in vivo was assessed by inhibition of [3H]flumazenil binding and correlated with the pharmacological effects. Although diazepam and triazolam produced effects beginning at low to intermediate fractional BZR occupancy, Ro 19-8022 and bretazenil required a higher BZR occupancy to do so, in accordance with their partial agonistic character. With the two full agonists, anticonvulsant and anticonflict activities were elicited at a lower fractional BZR occupancy than muscle relaxant and sedative effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318371

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABAA Receptors in a Rat Model of Essential Tremors.

Authors:  Dipak V Amrutkar; Tino Dyhring; Thomas A Jacobsen; Janus S Larsen; Karin Sandager-Nielsen
Journal:  Cerebellum       Date:  2020-04       Impact factor: 3.847

2.  Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.

Authors:  Jerri M Rook; Mohammed N Tantawy; Mohammad S Ansari; Andrew S Felts; Shaun R Stauffer; Kyle A Emmitte; Robert M Kessler; Colleen M Niswender; J Scott Daniels; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2014-09-22       Impact factor: 7.853

3.  Selective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513.

Authors:  Luanda J Pym; Susan M Cook; Thomas Rosahl; Ruth M McKernan; John R Atack
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846.

Authors:  K E Vanover; J E Barrett
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

5.  Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero.

Authors:  J R Martin; P Schoch; F Jenck; J L Moreau; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.

Authors:  Uwe Rudolph; Frédéric Knoflach
Journal:  Nat Rev Drug Discov       Date:  2011-07-29       Impact factor: 84.694

Review 7.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

8.  Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men.

Authors:  J Guldner; L Trachsel; C Kratschmayr; B Rothe; F Holsboer; A Steiger
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 9.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies.

Authors:  G H Jones; C Schneider; H H Schneider; J Seidler; B J Cole; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.